Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: kids  safety  medicine  health  fever  flu  children  spoon  dose  multivu  8171651  medicine  family  safety  health  pharmaceuticals  teeth  children  cold  probiotics  multivu  8134881  cancer  health  research  treatment  disease  2017  aacr  fda  multivu  8155051  fda  brain  cancer  health  healthcare  treatment  medicine  glioma  multivu  7944251  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951  csl  behring  global  biotherapeutics  medicine  study  research  fda  healthcare  health  multivu  8056151  medicine  cabinet  winter  makeover  tips  health  cold  clean  dispose  multivu  7974981  yas  island  travel  vacation  entertainment  sea  world  animals  marine  life  theme  park  research  multivu  8002251  yas  island  travel  vacation  entertainment  sea  world  animals  marine  life  theme  park  research  multivu  8002251  yas  island  travel  vacation  entertainment  sea  world  animals  marine  life  theme  park  research  multivu  8002251  research  blood  cancer  cancer  cure  treatment  health  medical  grants  fund  multivu  7554855  webmd  cancer  health  robin  roberts  dogs  detection  treatment  smell  medical  multivu  7579755 
Search // medicine
Results 1-12 of 124 for ' medicine ' (0 seconds)
Parents want to do the best for their children, especially when they’re not feeling well. That often means giving liquid, over-the-counter (OTC) medications when they have a cold, fever or the flu. But even the best intentions can go wrong when it comes to dosing children’s OTC medicines. OTC cough and cold medicines are safe and effective when used as directed – this includes always giving your child the precise, recommended dose. When it’s late at night and your child is sick, it may seem easier to reach for whatever is nearby, like a kitchen spoon, instead of taking the time to find the right dosing cup or syringe that came with the medicine. While 63 percent of parents surveyed say they prefer milliliter dosing devices to measure their children’s liquid medicine, 8 out of 10 parents* have given the wrong dose of liquid medicine to their child by accident. To view the multimedia release go to: https://www.multivu.com/players/English/8171651-chpa-educational-foundation-know-your-otcs/
Categories // Miscellaneous 
Added: 22 days ago by MultiVuVideos
Runtime: 0m30s | Views: 4 | Comments: 0
Not yet rated
 

 

 

Mark your calendars now – those leftover OTC and prescriptions in your medicine cabinet have got to go! Chances are, if you open your medicine cabinet, you’ll find some some leftover medication that “might come in handy someday.” The reality is, those medications may have expired and are either ineffective or may cause more harm than you know. With cold and flu season upon us, it’s a great time to purge the medicine cabinet. Better to prepare now than scramble when you are sick. Clean out clutter and stock up on the staples!
Categories // Miscellaneous 
Added: 41 days ago by MultiVuVideos
Runtime: 2m30s | Views: 2 | Comments: 0
Not yet rated
 

 

 

Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated. To view the multimedia release go to: https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Categories // Miscellaneous 
Added: 71 days ago by MultiVuVideos
Runtime: 1m0s | Views: 7 | Comments: 0
Not yet rated
 

 

 

A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma. The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor. To view the multimedia release go to: https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Categories // Miscellaneous 
Added: 154 days ago by MultiVuVideos
Runtime: 4m28s | Views: 8 | Comments: 0
Not yet rated
 

 

 

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Categories // Miscellaneous 
Added: 181 days ago by MultiVuVideos
Runtime: 3m35s | Views: 2 | Comments: 0
Not yet rated
 

 

 

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE. To view the multimedia release go to: https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Categories // Miscellaneous 
Added: 245 days ago by MultiVuVideos
Runtime: 2m41s | Views: 5 | Comments: 0
Not yet rated
 

 

 

You stock your kitchen’s pantry shelves with quality food. Why would you skimp on the shelves of your bathroom cabinet? With cold and flu season upon us, it’s a great time to purge the medicine cabinet. Better to shop and prepare now than scramble when you are sick. Clean out clutter, get rid of anything that’s expired or you aren’t using, and stock up on the staples. A fresh start can make all the difference. Well-known RN and health expert, Linda Ciampa has been helping families stay healthy for over a decade. On Wednesday, January 18th, Linda will be available for live interviews to share her best tips for preparing your medicine cabinet for the colder weather. She will also provide viewers with an easy-to-use option for keeping track of your family’s medical and fitness information.
Categories // Miscellaneous 
Added: 303 days ago by MultiVuVideos
Runtime: 5m6s | Views: 3 | Comments: 0
Not yet rated
 

 

 

Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement. The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience. To view the multimedia release go to: http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Categories // Miscellaneous 
Added: 344 days ago by MultiVuVideos
Runtime: 1m8s | Views: 54 | Comments: 0
Not yet rated
 

 

 

Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement. The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience. To view the multimedia release go to: http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Categories // Miscellaneous 
Added: 344 days ago by MultiVuVideos
Runtime: 1m39s | Views: 48 | Comments: 0
Not yet rated
 

 

 

Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement. The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience. To view the multimedia release go to: http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Categories // Miscellaneous 
Added: 344 days ago by MultiVuVideos
Runtime: 1m31s | Views: 151 | Comments: 0
    
 

 

 

The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide. This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers. To view the multimedia release go to: http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Categories // Miscellaneous 
Added: 372 days ago by MultiVuVideos
Runtime: 0m47s | Views: 71 | Comments: 0
Not yet rated
 

 

 

Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine. To view the multimedia release go to: http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
Categories // Miscellaneous 
Added: 372 days ago by MultiVuVideos
Runtime: 0m30s | Views: 47 | Comments: 0
Not yet rated
 

 

 

Page 1 of 11  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2017 ClipMoon.com. All rights reserved.